论文部分内容阅读
研究表明,冠心病危险,随着血浆总胆固醇和低密度脂蛋白-胆固醇(LDLc)浓度增高而递增。一般认为,血浆LDLc<3.90 mmol/L需开始治疗。对于Ⅱa型高脂血症,阴离子交换树脂消胆胺(Cholestyramine)和考来替泊(Colestipol)被列为首选,但胃肠道副作用多;每日口服吉非罗齐1.2g,可使LDLc下降10～15％。微孔型消胆胺类药物Filicol,胆酸结合力超过消胆胺,耐受性则相似。 50例ⅡHa型重度原发性高胆固醇血症(其中18例为杂合子型),随机口服Filicol粉剂(25例)3g每日3次(饭前),或吉非罗齐(25例)600mg每日2次,治疗12周。治疗前后测定血脂。治疗12周后,Filicol组血浆总胆固醇下降14％(P<0.001),LDLc下降20%(P<
Studies have shown that the risk of coronary heart disease, as plasma total cholesterol and low density lipoprotein - cholesterol (LDLc) concentrations increased. Generally believed that the plasma LDLc <3.90 mmol / L need to start treatment. For Type IIa hyperlipidemia, anion exchange resins Cholestyramine and Colestipol are listed as first choice, but gastrointestinal side effects are high. Daily oral administration of gemfibrozil at 1.2 g will allow LDLc Decline 10 ~ 15%. Micropore cholestyramine drug Filicol, cholic acid binding than cholestyramine, the tolerance is similar. 50 cases of type IIH severe primary hypercholesterolemia (18 cases of heterozygous), random oral Filicol powder (25 cases) 3g 3 times a day (before meals), or gemfibrozil (25 cases) 600mg Twice daily for 12 weeks. Blood lipids were measured before and after treatment. After 12 weeks of treatment, total cholesterol in Filicol group decreased by 14% (P <0.001) and LDLc decreased by 20% (P <